Literature DB >> 22960950

Clinical efficacy of laparoscopic sleeve gastrectomy vs laparoscopic gastric bypass in obese type 2 diabetic patients: a retrospective comparison.

P P Cutolo1, G Nosso, G Vitolo, V Brancato, B Capaldo, L Angrisani.   

Abstract

BACKGROUND: Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) are performed in patients with obesity and type 2 diabetes mellitus (T2DM). The aim of this study is to evaluate retrospectively the clinical efficacy of RYGB and SG in two groups of obese T2DM patients.
METHODS: From the hospital database, we extracted the clinical records of 31 obese T2DM patients, of whom 15 (7 F/8 M) had undergone laparoscopic SG (LSG) and 16 (7 F/9 M) laparoscopic RYGB (LRYGB) in the period 2005-2008. The groups were comparable for age (range 33-59 years) and BMI (range 38-57 kg/m(2)). LRYGB alimentary limb was 150 cm, and biliopancreatic limb was 150 cm from the Treitz ligament. LSG vertical transection was calibrated on a 40-Fr orogastric bougie. Data were analysed at 6, 12 and 18-24 months with reference to weight loss and remission of comorbidities.
RESULTS: The reduction in body weight was comparable in the two groups. At 18-24 months the percent BMI reduction was 29 ± 8 and 33 ± 11 % in LSG and LRYGB, respectively. Percent excess weight loss was 53 ± 16 and 52 ± 19 % in LSG and LRYGB, respectively. Thirteen patients in LSG and 14 patients in LRYGB discontinued their hypoglycaemic medications. Five (55 %) patients in LSG and eight (89 %) in LRYGB discontinued antihypertensive drugs. Three out of five patients in LSG and one out of two patients in LRYGB withdrew lipid-lowering agents.
CONCLUSIONS: LSG and LRYGB are equally effective in terms of weight loss and remission of obesity-related comorbidities. Controlled long-term comparisons are needed to establish the optimal procedure in relation to patients' characteristics.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22960950      PMCID: PMC4197913          DOI: 10.1007/s11695-012-0657-5

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  17 in total

Review 1.  Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition.

Authors:  Samuel Klein; Nancy F Sheard; Xavier Pi-Sunyer; Anne Daly; Judith Wylie-Rosett; Karmeen Kulkarni; Nathaniel G Clark
Journal:  Diabetes Care       Date:  2004-08       Impact factor: 19.112

Review 2.  Gastrointestinal surgery for severe obesity.

Authors: 
Journal:  Consens Statement       Date:  1991 Mar 25-27

3.  Metabolic/bariatric surgery Worldwide 2008.

Authors:  Henry Buchwald; Danette M Oien
Journal:  Obes Surg       Date:  2009-12       Impact factor: 4.129

4.  Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery.

Authors:  Caterina Guidone; Melania Manco; Elena Valera-Mora; Amerigo Iaconelli; Donatella Gniuli; Andrea Mari; Giuseppe Nanni; Marco Castagneto; Menotti Calvani; Geltrude Mingrone
Journal:  Diabetes       Date:  2006-07       Impact factor: 9.461

5.  Ghrelin enhances appetite and increases food intake in humans.

Authors:  A M Wren; L J Seal; M A Cohen; A E Brynes; G S Frost; K G Murphy; W S Dhillo; M A Ghatei; S R Bloom
Journal:  J Clin Endocrinol Metab       Date:  2001-12       Impact factor: 5.958

Review 6.  Bariatric surgery: a systematic review and network meta-analysis of randomized trials.

Authors:  R Padwal; S Klarenbach; N Wiebe; D Birch; S Karmali; B Manns; M Hazel; A M Sharma; M Tonelli
Journal:  Obes Rev       Date:  2011-03-28       Impact factor: 9.213

7.  Early experience with two-stage laparoscopic Roux-en-Y gastric bypass as an alternative in the super-super obese patient.

Authors:  J P Regan; W B Inabnet; M Gagner; A Pomp
Journal:  Obes Surg       Date:  2003-12       Impact factor: 4.129

Review 8.  Bariatric surgery: a systematic review and meta-analysis.

Authors:  Henry Buchwald; Yoav Avidor; Eugene Braunwald; Michael D Jensen; Walter Pories; Kyle Fahrbach; Karen Schoelles
Journal:  JAMA       Date:  2004-10-13       Impact factor: 56.272

9.  Sleeve gastrectomy as sole and definitive bariatric procedure: 5-year results for weight loss and ghrelin.

Authors:  Arthur Bohdjalian; Felix B Langer; Soheila Shakeri-Leidenmühler; Lisa Gfrerer; Bernhard Ludvik; Johannes Zacherl; Gerhard Prager
Journal:  Obes Surg       Date:  2010-01-22       Impact factor: 4.129

Review 10.  Gastrointestinal surgery as treatment for type 2 diabetes.

Authors:  Tracy-Ann Moo; Francesco Rubino
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2008-04       Impact factor: 3.243

View more
  19 in total

1.  Stapler-Less Robotic Partial Gastrectomy: a Safety and Feasibility Experimental Study.

Authors:  Tomasz Rogula; David Leifer; Jacob A Petrosky; Xiuli Liu; Michal Janik; Valerie Zeer; Piotr Fiedorczuk; Jan Baczek; Philip Schauer
Journal:  Obes Surg       Date:  2019-02       Impact factor: 4.129

2.  Predictive Value of Gut Peptides in T2D Remission: Randomized Controlled Trial Comparing Metabolic Gastric Bypass, Sleeve Gastrectomy and Greater Curvature Plication.

Authors:  Anna Casajoana; Jordi Pujol; Amador Garcia; Jordi Elvira; Nuria Virgili; Francisco Javier de Oca; Xavier Duran; Sonia Fernández-Veledo; Joan Vendrell; Nuria Vilarrasa
Journal:  Obes Surg       Date:  2017-09       Impact factor: 4.129

3.  Sleeve Gastrectomy vs Roux-en-Y Gastric Bypass. Data from IFSO-European Chapter Center of Excellence Program.

Authors:  John Melissas; Konstantinos Stavroulakis; Vassilis Tzikoulis; Angeliki Peristeri; John A Papadakis; Abdolreza Pazouki; Alireza Khalaj; Ali Kabir
Journal:  Obes Surg       Date:  2017-04       Impact factor: 4.129

4.  A meta-analysis of 2-year effect after surgery: laparoscopic Roux-en-Y gastric bypass versus laparoscopic sleeve gastrectomy for morbid obesity and diabetes mellitus.

Authors:  Chengda Zhang; Yuan Yuan; Cuiqiong Qiu; Weidong Zhang
Journal:  Obes Surg       Date:  2014-09       Impact factor: 4.129

5.  Effectiveness and Safety of Sleeve Gastrectomy, Gastric Bypass, and Adjustable Gastric Banding in Morbidly Obese Patients: a Multicenter, Retrospective, Matched Cohort Study.

Authors:  Kemal Dogan; Ralph P M Gadiot; Edo O Aarts; Bark Betzel; Cees J H M van Laarhoven; Laser U Biter; Guido H H Mannaerts; Theo J Aufenacker; Ignace M C Janssen; Frits J Berends
Journal:  Obes Surg       Date:  2015-07       Impact factor: 4.129

6.  Remission of Type 2 Diabetes and Sleeve Gastrectomy in Morbid Obesity: a Comparative Systematic Review and Meta-analysis.

Authors:  Ferdous Madadi; Rami Jawad; Ismail Mousati; Philip Plaeke; Guy Hubens
Journal:  Obes Surg       Date:  2019-12       Impact factor: 4.129

7.  Amelioration of glycemic control by sleeve gastrectomy and gastric bypass in a lean animal model of type 2 diabetes: restoration of gut hormone profile.

Authors:  Hans Eickhoff; Teresa M Louro; Paulo N Matafome; Filipa Vasconcelos; Raquel M Seiça; Francisco Castro E Sousa
Journal:  Obes Surg       Date:  2015-01       Impact factor: 4.129

8.  Analysis of the five-year outcomes of sleeve gastrectomy and mini gastric bypass: a report from the Indian sub-continent.

Authors:  K S Kular; N Manchanda; R Rutledge
Journal:  Obes Surg       Date:  2014-10       Impact factor: 4.129

9.  Effects of sleeve gastrectomy with jejuno-jejunal or jejuno-ileal loop on glycolipid metabolism in diabetic rats.

Authors:  Ming-Wei Zhong; Shao-Zhuang Liu; Guang-Yong Zhang; Xiang Zhang; San-Yuan Hu
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

10.  Laparoscopic sleeve gastrectomy versus laparoscopic Roux-en-Y gastric bypass for morbid obesity and related comorbidities: a meta-analysis of 21 studies.

Authors:  Yong Zhang; Ju Wang; Wang Ju; Xiangyu Sun; Zhangou Cao; Zhanguo Cao; Xinsheng Xu; Xu Xinsheng; Daquan Liu; Liu Daquan; Xiangyang Xin; Xin Xiangyang; Mingfang Qin
Journal:  Obes Surg       Date:  2015-01       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.